S. Shastri, M.D.; Robert E. Slayton, M.D.; Janet Wolter, M.D.; Charles P. Perlia, M.D., F.A.C.P.
This content is PDF only. Please click on the PDF icon to access.
Bleomycin, an antibiotic derived from Streptomyces verticillus, has recently become available for clinical trial in this country. Over 50 patients admitted to Rush-Presbyterian-St. Luke's Medical Center Hospital, Chicago, Ill., with various types of disseminated cancer were studied. An initial testing dose of 15 mg of the drug, followed by 30 mg twice a week, intravenously or intramuscularly, was administered. Objective regression of the tumors was noted in patients with epidermoid carcinoma of the head and neck region, uterine cervix, Hodgkin's disease and other lymphomas, embryonal carcinoma of the testes, and in a patient with lymphangiosarcoma of the arm. Serial biopsies
Shastri S, Slayton RE, Wolter J, et al. Clinical Study with Bleomycin.. Ann Intern Med. 1971;74:837–838. doi: https://doi.org/10.7326/0003-4819-74-5-837_4
Download citation file:
Published: Ann Intern Med. 1971;74(5):837-838.
Copyright © 2020 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use